RS-2024-00335179

Phase 1 clinical development of PG-102, a next-generation GLP-1/GLP-2 dual agonist for treating obesity and diabetes

ProGen Co., Ltd.

Disease area	***Metabolic diseases***
Product Type	Bispecific fusion protein
Indication	Obesity, Type 2 Diabetes
Target	GLP-1R and GLP-2R

Mechanism of Action



A biased GLP-1R/GLP-2R dual agonist with extended PK properties

- Relative potency of PG-102 against GLP-1 receptor and GLP-2 receptor is sophisticatedly optimized for simultaneously activation of both receptors.
- PG-102 also features NTIG®, a long-acting Fc platform technology, for a prolonged action.

Competitiveness

Efficacy	• **Superior quality of body weight loss compared to Tirzepatide** Fat mass loss ↑ + lean mass loss ↓	Data 1
	• **Breakthrough glycemic control compared to Semaglutide and Tirzepatide** Glucose uptake ↑ + β-cell protection	Data 2
	• **Comorbidity prevention in obesity/diabetes**	Data 3
Safety	• **Improved safety & tolerability** Gastrointestinal tract inflammation ↓	Data 3
Convenience	• **Extended dosing interval allowing for at least biweekly to monthly administration**	

Development Stage	***Phase 1b***
Route of Administration	Subcutaneous injection

Key Data

1. PG-102 achieves comprehensive weight loss and enhanced fat-to-lean loss ratio compared to Dapiglutide and Tirzepatide



Comparable body weight loss



Outstanding increase in fat-to-lean loss ratio

2. PG-102 excels in glycemic control, achieves normoglycemia, and enhances β-cell protection compared to Semaglutide and Tirzepatide



Superior reduction in glycated hemoglobin



Effective pancreatic β–cell protection

3. PG-102 demonstrates effective prevention of comorbidities through superior systemic inflammation control



Inhibition of hepatocyte damage



Elevated expression of tight junction related proteins



Exceptional reduction in hepatic triglycerides and steatohepatitis levels

IP	KR Registered (KR10-2349717, KR10-2349718) Under review in Key countries (including US, EP, CN, ID, BR)